Algorae Pharmaceuticals Ltd Appoints Nasdaq Pharma Chair Troy Valentine [VIDEO]
Algorae Pharmaceuticals (ASX: 1AI) has appointed Troy Valentine — chairman of Nasdaq-listed Incannex Healthcare and architect of over A$220 million in capital raisings — as a Non-Executive Director to drive its dual AlgoraeRx and AlgoraeOS growth strategy.
Key Takeaways
- Troy Valentine joins the Algorae board effective 14 July 2026 as a Non-Executive Director, bringing more than 30 years of finance and board experience including chairmanship of Nasdaq-listed Incannex Healthcare Inc.
- Valentine oversaw capital raisings in excess of A$220 million at Incannex and guided the company to FDA Fast Track designation for its lead sleep apnoea candidate in December 2025, providing directly relevant clinical-stage and capital markets credentials.
- AlgoraeOS v2 validation results from Peter MacCallum Cancer Centre, published in July 2026, showed the AI platform identifying synergistic drug combinations at approximately 2.5 times the rate of its predecessor, providing independent scientific support for the asset Valentine's appointment is partly designed to help scale.
- Brad Dilkes resigned as a Director on the same date, 14 July 2026, making this a board composition change rather than a simple addition to the existing structure.
- Valentine's appointment remains subject to shareholder election at Algorae's next Annual General Meeting, in accordance with the company's constitution and ASX Listing Rules.
![Immuron Ltd Engages Pullan Consulting for IMM-529 Partnering Strategy [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fce7cfc09-0087-4fd3-8a56-86ebd3a896c82Fimage_0.jpg)
![Algorae Pharmaceuticals Ltd AI Platform Validated With 2.5x Synergy Lift [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fb9b14ab6-a11f-47ad-85bf-491be1bf9b582Fimage_0.jpg)
![Genetic Signatures Ltd Gets BCAL Backing Through 10.2% Stake Purchase [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fb377bf6c-56e4-43e5-9dd1-8e08cd86e8c82Fimage_0.jpg)
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.